NCT05013723View on ClinicalTrials.gov

Impact of Monoclonal Antibody Treatment on Post-Acute COVID-19 Syndrome

CompletedOBSERVATIONAL

Enrollment

260

Participants

Timeline

Start Date

August 30, 2021

Primary Completion Date

December 16, 2022

Study Completion Date

December 16, 2022

Conditions

"Post-acute COVID-19 (PACS), or long COVID Syndrome"

Interventions

OTHER

Surveys

Mental health validated psychometric surveys: Depression (PHQ-9), Anxiety (GAD-7), PTSD (PC-PTSD-5) Quality of Life surveys: Post COVID-19 Function Status Scale, Quality of life (SF-12)

Trial Locations (1)

84157

Intermountain Medical Center, Murray

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Intermountain Health Care, Inc.

OTHER

NCT05013723 - Impact of Monoclonal Antibody Treatment on Post-Acute COVID-19 Syndrome | Biotech Hunter | Biotech Hunter